CN109700818A - A kind of pharmaceutical composition of reducing weight and blood fat and preparation method thereof and purposes - Google Patents
A kind of pharmaceutical composition of reducing weight and blood fat and preparation method thereof and purposes Download PDFInfo
- Publication number
- CN109700818A CN109700818A CN201711007704.1A CN201711007704A CN109700818A CN 109700818 A CN109700818 A CN 109700818A CN 201711007704 A CN201711007704 A CN 201711007704A CN 109700818 A CN109700818 A CN 109700818A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- phloridzin
- isoquercitrin
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 76
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 210000004369 blood Anatomy 0.000 title claims abstract description 20
- 239000008280 blood Substances 0.000 title claims abstract description 20
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 claims abstract description 62
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims abstract description 62
- IOUVKUPGCMBWBT-DARKYYSBSA-N Phloridzin Natural products O[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-DARKYYSBSA-N 0.000 claims abstract description 62
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 claims abstract description 62
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 claims abstract description 62
- IOUVKUPGCMBWBT-QNDFHXLGSA-N phlorizin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-QNDFHXLGSA-N 0.000 claims abstract description 62
- 235000019139 phlorizin Nutrition 0.000 claims abstract description 62
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 claims abstract description 62
- 230000000694 effects Effects 0.000 claims abstract description 48
- 239000000126 substance Substances 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 38
- 239000000284 extract Substances 0.000 claims description 47
- 235000020717 hawthorn extract Nutrition 0.000 claims description 31
- 240000000249 Morus alba Species 0.000 claims description 30
- 235000008708 Morus alba Nutrition 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- -1 emplastrum Substances 0.000 claims description 2
- 239000010408 film Substances 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000003973 paint Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 241000700159 Rattus Species 0.000 description 15
- 239000002671 adjuvant Substances 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 238000000227 grinding Methods 0.000 description 9
- 108010028554 LDL Cholesterol Proteins 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 102000019280 Pancreatic lipases Human genes 0.000 description 3
- 108050006759 Pancreatic lipases Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000003579 anti-obesity Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PWDLDBWXTVILPC-WGAVTJJLSA-N CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 Chemical compound CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 PWDLDBWXTVILPC-WGAVTJJLSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960005060 lorcaserin Drugs 0.000 description 2
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 102000009394 5-Hydroxytryptamine 2C receptors Human genes 0.000 description 1
- 108050000259 5-Hydroxytryptamine 2C receptors Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241001092040 Crataegus Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 229910003978 SiClx Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000002201 avitaminosis Nutrition 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940103440 qsymia Drugs 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to pharmaceutical composition of a kind of reducing weight and blood fat and preparation method thereof and purposes.The pharmaceutical composition, including following bulk pharmaceutical chemicals: with the poidometer of phloridzin, phloridzin or its pharmaceutically acceptable salt 22-55 parts by weight；With the poidometer of isoquercitrin, isoquercitrin or its pharmaceutically acceptable salt 20-73 parts by weight.The pharmaceutical composition not only has significant fat-reducing effect, and fat-reducing effect is significantly better than the fat-reducing effect of single bulk pharmaceutical chemicals, has the function of synergy；And the pharmaceutical composition has significant lipid-lowering effect, and lipid-lowering effect is significantly better than the lipid-lowering effect of single bulk pharmaceutical chemicals, has the function of significant synergy.
Description
Technical field
The invention belongs to health care product or medicine fields, are related to a kind of pharmaceutical composition and preparation method thereof of reducing weight and blood fat
With purposes.
Background technique
Obesity is showed an increasing trend year by year, is had become as a kind of most common chronic incretion metabolism disease, disease incidence
For global publilc health problem.Fat degree is generally indicated with body mass index (BMI), knits (WHO) by world health
Specialists meeting work out international standard, 24≤BMI<28 be it is overweight, BMI>30 be obesity.The statistical result of WHO shows at present
It is overweight that the whole world has more than 1,000,000,000 adults, and wherein at least 300,000,000 people are fat.It is super by 2015 if not taking any effective measures
Weight number is up to 1,500,000,000.Obesity can cause many health problems, not only will increase hypertension, coronary heart disease, diabetes B
Morbidity and mortality also easily cause the disease of respiratory system complication, osteoarthritis and spirit aspect.
Currently, weight-reducing mainly uses two methods of weight reduction with drugs and weight-reducing by dieting.Current slimming drugs mainly include following
Two major classes: pancreatic lipase inhibitor and appetite inhibitor；Pancreatic lipase inhibitor he pass through inhibit pancreatic lipase activity, press down
Fatty decomposition absorbs and loses weight in food processed, and appetite inhibitor is made due to that can cause nervous system adverse reaction by limitation
With.So far, the slimming drugs that can be used for a long time through FDA approval only have lipase inhibitor orlistat (orlistat), 5-
Hydroxytryptamine 2C receptor stimulating agent lorcaserin (lorcaserin) and compound slimming medicine Qsymia (containing phentermine and Topiramate
Sustained release agent).However, above-mentioned slimming drugs can cause the adverse reactions such as steatorrhea, fat-soluble avitaminosis, and to brain centres
Whether toxic side effect still has very big uncertainty with cardiovascular system etc..
Hyperlipidemia is that fat metabolism or operating exception make one or more lipid levels in blood plasma be higher than the complete of normal value
Body disease is mainly characterized by triacylglycerol in serum (TG), total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C)
Level increases, and high-density lipoprotein cholesterol (HDL-C) is horizontal to be reduced.Hyperlipidemia be cause cardiovascular and cerebrovascular disease the reason of it
One.According to statistics, there are about 12,000,000 people to die of cardiovascular and cerebrovascular disease every year in the whole world.Currently, the clinical first-line drug of reducing blood lipid is main
It is curative for effect, rapid-action for statins, but have the shortcomings that easily rebound, high recurrence rate and need Long-term taking medicine.
2001, cerivastatin caused to quit listing because the lethal serious adverse reaction of rhabdomyolysis occurs for pill taker, while also causing
It worry to the safety of other statins and discusses warmly.
Although there is document report phloridzin that there is effect for reducing blood fat in the prior art, also there is document report isoquercitrin that can make
For fat and related metabolic diseases potential treatment drug, but the medicine group still without both phloridzin and isoquercitrin composition
Close the relevant report that object has reducing blood lipid or antiobesity action.
Summary of the invention
For this purpose, in a first aspect, the embodiment of the invention provides a kind of pharmaceutical composition, including following bulk pharmaceutical chemicals:
With the poidometer of phloridzin, phloridzin or its pharmaceutically acceptable salt 22-55 parts by weight；
With the poidometer of isoquercitrin, isoquercitrin or its pharmaceutically acceptable salt 20-73 parts by weight.
Preferably, aforementioned pharmaceutical compositions, including following bulk pharmaceutical chemicals:
With the poidometer of phloridzin, phloridzin or its pharmaceutically acceptable salt 27-52 parts by weight；
With the poidometer of isoquercitrin, isoquercitrin or its pharmaceutically acceptable salt 48-73 parts by weight.
It is further preferred that aforementioned pharmaceutical compositions, including following bulk pharmaceutical chemicals:
27 parts by weight of phloridzin, 73 parts by weight of isoquercitrin；Or
38 parts by weight of phloridzin, 62 parts by weight of isoquercitrin；Or
52 parts by weight of phloridzin, 48 parts by weight of isoquercitrin.
Preferably, aforementioned pharmaceutical compositions further include the following raw material medicine: haw thorn extract 22-43 parts by weight.
It is further preferred that aforementioned pharmaceutical compositions, including following bulk pharmaceutical chemicals:
With the poidometer of phloridzin, phloridzin or its pharmaceutically acceptable salt 22-55 parts by weight；
With the poidometer of isoquercitrin, isoquercitrin or its pharmaceutically acceptable salt 23-35 parts by weight；
Haw thorn extract 22-43 parts by weight.
It is further preferred that aforementioned pharmaceutical compositions, including following bulk pharmaceutical chemicals:
55 parts by weight of phloridzin, 23 parts by weight of isoquercitrin, 22 parts by weight of haw thorn extract；Or
22 parts by weight of phloridzin, 35 parts by weight of isoquercitrin, 43 parts by weight of haw thorn extract；Or
33 parts by weight of phloridzin, 28 parts by weight of isoquercitrin, 39 parts by weight of haw thorn extract.
Preferably, the following steps are included: taking Fructus Crataegi, alcohol extracting merges and extracts the preparation method of the haw thorn extract
Liquid, concentration to get.
It is further preferred that the preparation method of the haw thorn extract the following steps are included: take Fructus Crataegi, is heated to reflux
It extracts 1-5 times, the ethanol water that the volume fraction that 5-10 times of weight is added every time is 10-50% extracts 0.5-3 hours, merges
Extracting solution, concentration, it is dry to get.
It is further preferred that the preparation method of the haw thorn extract the following steps are included: take Fructus Crataegi, heats back
Stream extracts 2 times, and the ethanol water that the volume fraction that 8 times of weight is added every time is 30% extracts 1 hour, and combined extract is dense
Contracting, it is dry to get.
Preferably, aforementioned pharmaceutical compositions further include the following raw material medicine: extract of mulberry twig 17-42 parts by weight.
It is further preferred that aforementioned pharmaceutical compositions, including following bulk pharmaceutical chemicals:
With the poidometer of phloridzin, phloridzin or its pharmaceutically acceptable salt 26-33 parts by weight；
With the poidometer of isoquercitrin, isoquercitrin or its pharmaceutically acceptable salt 25-47 parts by weight；
Extract of mulberry twig 27-42 parts by weight.
It is further preferred that aforementioned pharmaceutical compositions, including following bulk pharmaceutical chemicals:
33 parts by weight of phloridzin, 25 parts by weight of isoquercitrin, 42 parts by weight of extract of mulberry twig；Or
26 parts by weight of phloridzin, 47 parts by weight of isoquercitrin, 27 parts by weight of extract of mulberry twig；Or
30 parts by weight of phloridzin, 29 parts by weight of isoquercitrin, 41 parts by weight of extract of mulberry twig.
Preferably, the preparation method of the extract of mulberry twig is the following steps are included: take ramulus mori, alcohol extracting, and combined extract is dense
Contracting to get.
It is further preferred that the preparation method of the extract of mulberry twig is the following steps are included: take ramulus mori, heating and refluxing extraction
1-5 times, the ethanol water that the volume fraction that 8-12 times of weight is added every time is 30-70% extracts 0.5-3 hours, merges and extracts
Liquid, concentration, it is dry to get.
It is further preferred that the preparation method of the extract of mulberry twig the following steps are included: take ramulus mori, is heated to reflux and mentions
It taking 2 times, the ethanol water that the volume fraction that 10 times of weight is added every time is 50% extracts 1 hour, combined extract, concentration,
It is dry to get.
Preferably, aforementioned pharmaceutical compositions further include the following raw material medicine: haw thorn extract 22-43 parts by weight, and ramulus mori extracts
Object 17-42 parts by weight.
It is further preferred that aforementioned pharmaceutical compositions, including following bulk pharmaceutical chemicals:
With the poidometer of phloridzin, phloridzin or its pharmaceutically acceptable salt 31-39 parts by weight；
With the poidometer of isoquercitrin, isoquercitrin or its pharmaceutically acceptable salt 18-22 parts by weight；
Haw thorn extract 25-31 parts by weight, extract of mulberry twig 15-19 parts by weight.
It is further preferred that aforementioned pharmaceutical compositions, including following bulk pharmaceutical chemicals:
35 parts by weight of phloridzin, 20 parts by weight of isoquercitrin, 28 parts by weight of haw thorn extract, 17 weight of extract of mulberry twig
Part；Or
31 parts by weight of phloridzin, 22 parts by weight of isoquercitrin, 25 parts by weight of haw thorn extract, 19 weight of extract of mulberry twig
Part；Or
39 parts by weight of phloridzin, 18 parts by weight of isoquercitrin, 31 parts by weight of haw thorn extract, 15 weight of extract of mulberry twig
Part.
Second aspect, the embodiment of the invention also provides the preparation methods of aforementioned pharmaceutical compositions, comprising the following steps:
The phloridzin or its pharmaceutically acceptable salt, isoquercitrin or its is pharmaceutically acceptable of selected parts by weight are taken respectively
Salt, grinding, be uniformly mixed to get；Or
The phloridzin or its pharmaceutically acceptable salt, isoquercitrin or its is pharmaceutically acceptable of selected parts by weight are taken respectively
Salt, haw thorn extract, grinding, be uniformly mixed to get；Or
The phloridzin or its pharmaceutically acceptable salt, isoquercitrin or its is pharmaceutically acceptable of selected parts by weight are taken respectively
Salt, extract of mulberry twig, grinding, be uniformly mixed to get；Or
The phloridzin or its pharmaceutically acceptable salt, isoquercitrin or its is pharmaceutically acceptable of selected parts by weight are taken respectively
Salt, haw thorn extract, extract of mulberry twig, grinding, be uniformly mixed to get.
The third aspect, the embodiment of the invention also provides a kind of pharmaceutical preparations, using aforementioned pharmaceutical compositions as active constituent,
Customary adjuvant is added, clinically acceptable tablet, capsule, powder, pill, granule, syrup is made according to common process
Agent, injection, solution, mixture, lotion, paint, film, emplastrum, ointment, suppository, paste, gelling agent, aerosol or
Spray.
The customary adjuvant are as follows: filler, disintegrating agent, lubricant, suspending agent, adhesive, sweetener, corrigent, anti-corrosion
Agent, matrix etc..Filler includes: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose etc.；It collapses
Solving agent includes: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone, low substitution hydroxyl
Third cellulose, cross-linked carboxymethyl cellulose are received；Lubricant includes: magnesium stearate, lauryl sodium sulfate, talcum powder, dioxy
SiClx etc.；Suspending agent includes: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methyl cellulose etc.；Bonding
Agent includes starch slurry, polyvinylpyrrolidone, hydroxypropyl methyl cellulose etc.；Sweetener includes: saccharin sodium, aspartame, sugarcane
Sugar, honey element, enoxolone etc.；Corrigent includes: sweetener and various essence；Preservative include: parabens, benzoic acid,
Sodium benzoate, sorbic acid and its esters, benzalkonium bromide, the fixed, eucalyptus oil of acetic acid chloroethene etc.；Matrix include: PEG6000,
PEG4000, insect wax etc..
Fourth aspect, the embodiment of the invention also provides aforementioned pharmaceutical compositions or said medicine preparation to have in preparation
The drug of antiobesity action or the application in health care product.
5th aspect, the embodiment of the invention also provides aforementioned pharmaceutical compositions or said medicine preparation to have in preparation
The drug of effect for reducing blood fat or the application in health care product.
Technical solution of the present invention has the advantages that
(1) the research of the invention finds that, with phloridzin or its pharmaceutically acceptable salt, isoquercitrin or its can pharmaceutically connect
The salt received is that pharmaceutical composition, the two mutual cooperation, collective effect under specific proportion, so that the medicine group is made in bulk pharmaceutical chemicals
Closing object not only has significant fat-reducing effect, and fat-reducing effect is significantly better than the fat-reducing effect of single bulk pharmaceutical chemicals, and there is collaboration to increase
The effect of effect；And the pharmaceutical composition has significant lipid-lowering effect, and lipid-lowering effect is significantly better than single bulk pharmaceutical chemicals
Lipid-lowering effect, have the function of significant synergy.
(2) present invention further study show that, with phloridzin or its pharmaceutically acceptable salt, isoquercitrin or its pharmacy
Upper acceptable salt, haw thorn extract are that pharmaceutical composition is made in bulk pharmaceutical chemicals, and three cooperates under specific proportion, is common
Effect, so that the pharmaceutical composition not only has significant fat-reducing effect, fat-reducing effect is significantly better than subtracting for single bulk pharmaceutical chemicals
Fertilizer efficiency fruit has the function of synergy；And the pharmaceutical composition has significant lipid-lowering effect, and lipid-lowering effect is aobvious
The lipid-lowering effect for being better than single bulk pharmaceutical chemicals is write, has the function of significant synergy.
(3) present invention further study show that, with phloridzin or its pharmaceutically acceptable salt, isoquercitrin or its pharmacy
Upper acceptable salt, extract of mulberry twig are that pharmaceutical composition is made in bulk pharmaceutical chemicals, and three cooperates under specific proportion, is common
Effect, so that the pharmaceutical composition not only has significant fat-reducing effect, fat-reducing effect is significantly better than subtracting for single bulk pharmaceutical chemicals
Fertilizer efficiency fruit has the function of synergy；And the pharmaceutical composition has significant lipid-lowering effect, and lipid-lowering effect is aobvious
The lipid-lowering effect for being better than single bulk pharmaceutical chemicals is write, has the function of significant synergy.
(4) present invention further study show that, with phloridzin or its pharmaceutically acceptable salt, isoquercitrin or its pharmacy
Upper acceptable salt, haw thorn extract, extract of mulberry twig are that bulk pharmaceutical chemicals are made pharmaceutical composition, four under specific proportion phase
Mutually cooperation, collective effect, so that the pharmaceutical composition not only has significant fat-reducing effect, fat-reducing effect is significantly better than single
The fat-reducing effect of bulk pharmaceutical chemicals has the function of synergy；And the pharmaceutical composition has significant lipid-lowering effect, drop
Blood lipid significant effect is better than the lipid-lowering effect of single bulk pharmaceutical chemicals, has the function of significant synergy.
(5) present invention by Extraction solvent of the ethanol water of certain concentration 10-50% further the study found that extract
The haw thorn extract of preparation can make the active constituent in hawthorn farthest be extracted, in the above way prepare
Haw thorn extract combine other bulk pharmaceutical chemicals and be made pharmaceutical composition, the effect of weight-reducing and reducing blood lipid is more significant.
(6) present invention by Extraction solvent of the ethanol water of certain concentration 30-70% further the study found that extract
The extract of mulberry twig of preparation can make the active constituent in ramulus mori farthest be extracted, in the above way prepare
Extract of mulberry twig combine other bulk pharmaceutical chemicals and be made pharmaceutical composition, the effect of weight-reducing and reducing blood lipid is more significant.
Specific embodiment
In following embodiment of the present invention and experimental example, the preparation method of (1) haw thorn extract is the following steps are included: take drying
Fructus Crataegi, crush, heating and refluxing extraction 2 times, every time be added 8 times of weight volume fraction be 30% ethanol water mention
Take 1 hour, combined extract, be concentrated, it is dry to get.(2) preparation method of extract of mulberry twig is the following steps are included: take drying
Ramulus mori, crush, heating and refluxing extraction 2 times, every time be added 10 times of weight volume fraction be 50% ethanol water extract 1
Hour, combined extract, concentration, it is dry to get.(3) phloridzin and isoquercitrin are commercially available, and purity >=98%.
Embodiment 1
The bulk pharmaceutical chemicals of the pharmaceutical composition of the present embodiment form are as follows: phloridzin 27g, isoquercitrin 73g.
The pharmaceutical composition the preparation method comprises the following steps: take the phloridzin of selected weight, isoquercitrin respectively, grind, mixing is equal
It is even to get.
The pharmaceutical composition of the present embodiment is added customary adjuvant and tablet is made according to common process.
Embodiment 2
The bulk pharmaceutical chemicals of the pharmaceutical composition of the present embodiment form are as follows: phloridzin 38g, isoquercitrin 62g.
The pharmaceutical composition the preparation method comprises the following steps: take the phloridzin of selected weight, isoquercitrin respectively, grind, mixing is equal
It is even to get.
The pharmaceutical composition of the present embodiment is added customary adjuvant and capsule is made according to common process.
Embodiment 3
The bulk pharmaceutical chemicals of the pharmaceutical composition of the present embodiment form are as follows: phloridzin 52g, isoquercitrin 48g.
The pharmaceutical composition the preparation method comprises the following steps: take the phloridzin of selected weight, isoquercitrin respectively, grind, mixing is equal
It is even to get.
The pharmaceutical composition of the present embodiment is added customary adjuvant and granule is made according to common process.
Embodiment 4
The bulk pharmaceutical chemicals of the pharmaceutical composition of the present embodiment form are as follows: phloridzin 55g, isoquercitrin 23g, haw thorn extract
22g。
The pharmaceutical composition the preparation method comprises the following steps: take the phloridzin of selected weight, isoquercitrin, haw thorn extract respectively,
Grinding, be uniformly mixed to get.
The pharmaceutical composition of the present embodiment is added customary adjuvant and tablet is made according to common process.
Embodiment 5
The bulk pharmaceutical chemicals of the pharmaceutical composition of the present embodiment form are as follows: phloridzin 22g, isoquercitrin 35g, haw thorn extract
43g。
The pharmaceutical composition the preparation method comprises the following steps: take the phloridzin of selected weight, isoquercitrin, haw thorn extract respectively,
Grinding, be uniformly mixed to get.
The pharmaceutical composition of the present embodiment is added customary adjuvant and granule is made according to common process.
Embodiment 6
The bulk pharmaceutical chemicals of the pharmaceutical composition of the present embodiment form are as follows: phloridzin 33g, isoquercitrin 25g, extract of mulberry twig
42g。
The pharmaceutical composition the preparation method comprises the following steps: take the phloridzin of selected weight, isoquercitrin, extract of mulberry twig respectively,
Grinding, be uniformly mixed to get.
The pharmaceutical composition of the present embodiment is added customary adjuvant and capsule is made according to common process.
Embodiment 7
The bulk pharmaceutical chemicals of the pharmaceutical composition of the present embodiment form are as follows: phloridzin 26g, isoquercitrin 47g, extract of mulberry twig
27g。
The pharmaceutical composition the preparation method comprises the following steps: take the phloridzin of selected weight, isoquercitrin, extract of mulberry twig respectively,
Grinding, be uniformly mixed to get.
The pharmaceutical composition of the present embodiment is added customary adjuvant and tablet is made according to common process.
Embodiment 8
The bulk pharmaceutical chemicals of the pharmaceutical composition of the present embodiment form are as follows: phloridzin 35g, isoquercitrin 20g, haw thorn extract
28g, extract of mulberry twig 17g.
The pharmaceutical composition the preparation method comprises the following steps: take respectively the phloridzin of selected weight, isoquercitrin, haw thorn extract,
Extract of mulberry twig, grinding, be uniformly mixed to get.
The pharmaceutical composition of the present embodiment is added customary adjuvant and tablet is made according to common process.
Experimental example 1The research of present composition fat-reducing and antihyperglycemic
1, experimental material
Cholesterol and sodium taurocholate are purchased from Great Wall pharmaceutcal corporation, Ltd (China, Shanghai).
Feed be it is commercially available, high lipid food include 75% basal feed, 2% cholesterol, 0.5% sodium taurocholate, 15% lard and
7.5% yolk.
4 week old male SD rat of cleaning grade 150 (is provided by Shanghai Ling Chang Biotechnology Co., Ltd；Original body mass is
150-180g；The sub-cage rearing in plastics cage tool freely ingests and drinks water 7 days, adapts it to environment and quarantine).
2, experimental method
2.1 experimental group
140 that weight is concentrated are chosen from 150 rats, stochastic averagina is divided into 14 groups, every group 10, respectively tests
Group 1-8 group, control group 1-4 group, model control group and blank control group.Blank control group is fed with basal feed, other each groups are equal
It is fed with high lipid food.
2.2 medication
The embodiment 1-8 pharmaceutical composition 80mg/kg of preparation is given in stomach-filling to experimental group 1-8 group respectively；Control group 1-4 component
Phloridzin 80mg/kg, isoquercitrin 80mg/kg, haw thorn extract 80mg/kg, extract of mulberry twig 80mg/kg are not given；Model
Control group and blank control group give same amount of normal saline.
Each group is administered once/day, and successive administration 7 weeks.
3, experimental data detection and processing
3.1 Testing index
(1) after being administered 7 weeks, the weight and weight gain of each group are observed and recorded；
(2) after etherization, separation surrounding genital, kidney peripheral adipose pad and omental adipose weighing, according to formula rouge
Body ratio (%)=(surrounding genital fat+perirenal fat+omental adipose)/weight × 100% calculates rouge body ratio.
(3) after being administered 7 weeks, rat is taken a blood sample through retroorbital venous clump, fixed using enzymatic method on automatic biochemistry analyzer
Amount detection its serum triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein
Cholesterol (LDL-C).
3.2 statistical analysis
Data processing is carried out using 20.0 software of SPSS, group difference uses one-way analysis of variance.
4, experimental result
4.1 weight-reducing experiment results
After being administered 7 weeks, weight gain, the experimental data of rouge body ratio of each group rat are as shown in table 1.
The weight gain of 1 each group rat body weight of table, rouge body ratio
##It indicates to compare P < 0.01 with blank control group,**It indicates to compare P < 0.01 with model control group,*It indicates and model pair
P < 0.05 is compared according to group
As shown in Table 1: (1) rat feeding 7 week after, compared with blank control group, the weight gain of model control group rat body weight,
Rouge body ratio has extremely significant difference (P < 0.01), this shows obese model modeling success；
(2) compared with model control group, the weight gain of experimental group 1-8 group rat body weight significantly reduces (P < 0.01), this shows
The pharmaceutical composition of embodiment 1-8 preparation can significantly lose weight, and slow down body weight increase；
(3) compared with model control group, control group 1-4 group has the tendency that losing weight, but its effect for losing weight
The significant effect to lose weight not as good as experimental group 1-8 group.
4.2 lipid-lowering test results
After being administered 7 weeks, the experimental result of the biochemical blood parameters of each group rat is as shown in table 2.
The biochemical blood parameters of 2 each group rat of table
##It indicates to compare P < 0.01 with blank control group,**It indicates to compare P < 0.01 with model control group,*It indicates and model pair
P < 0.05 is compared according to group
As shown in Table 2: (1) after rat feeding 7 weeks, compared with blank control group, the blood of model control group rat is raw
The raising for changing parameter TG, TC, LDL-C has extremely significant difference (P < 0.01), this shows high blood lipid model modeling success；
(2) compared with model control group, the reduction of biochemical blood parameters TG, TC, LDL-C of experimental group 1-8 group rat have
Significant difference or extremely significant difference (P < 0.05 or P < 0.01)；
(3) compared with model control group, the reduction of biochemical blood parameters TG, TC, LDL-C of control group 1-4 group rat are not
Significantly.
5, experiment conclusion
(1) pharmaceutical composition of the present invention has significant antiobesity action, and the fat-reducing effect of the pharmaceutical composition is significantly better than
The fat-reducing effect of single bulk pharmaceutical chemicals has the function of synergy；(2) pharmaceutical composition of the present invention to the TG of hyperlipemia rat,
TC, LDL-C have balanced reduction effect, and the lipid-lowering effect of the pharmaceutical composition is significantly better than the reducing blood lipid of single bulk pharmaceutical chemicals
Effect has the function of synergy.
Obviously, the above embodiments are merely examples for clarifying the description, and does not limit the embodiments.It is right
For those of ordinary skill in the art, can also make on the basis of the above description it is other it is various forms of variation or
It changes.There is no necessity and possibility to exhaust all the enbodiments.And it is extended from this it is obvious variation or
It changes still within the protection scope of the invention.
Claims (10)
1. a kind of pharmaceutical composition, which is characterized in that including following bulk pharmaceutical chemicals:
With the poidometer of phloridzin, phloridzin or its pharmaceutically acceptable salt 22-55 parts by weight；
With the poidometer of isoquercitrin, isoquercitrin or its pharmaceutically acceptable salt 20-73 parts by weight.
2. pharmaceutical composition according to claim 1, which is characterized in that including following bulk pharmaceutical chemicals:
With the poidometer of phloridzin, phloridzin or its pharmaceutically acceptable salt 27-52 parts by weight；
With the poidometer of isoquercitrin, isoquercitrin or its pharmaceutically acceptable salt 48-73 parts by weight.
3. pharmaceutical composition according to claim 1 or 2, which is characterized in that further include the following raw material medicine: haw thorn extract
22-43 parts by weight.
4. pharmaceutical composition according to claim 3, which is characterized in that including following bulk pharmaceutical chemicals:
With the poidometer of phloridzin, phloridzin or its pharmaceutically acceptable salt 22-55 parts by weight；
With the poidometer of isoquercitrin, isoquercitrin or its pharmaceutically acceptable salt 23-35 parts by weight；
Haw thorn extract 22-43 parts by weight.
5. pharmaceutical composition according to claim 1 or 2, which is characterized in that further include the following raw material medicine: extract of mulberry twig
17-42 parts by weight.
6. pharmaceutical composition according to claim 5, which is characterized in that including following bulk pharmaceutical chemicals:
With the poidometer of phloridzin, phloridzin or its pharmaceutically acceptable salt 26-33 parts by weight；
With the poidometer of isoquercitrin, isoquercitrin or its pharmaceutically acceptable salt 25-47 parts by weight；
Extract of mulberry twig 27-42 parts by weight.
7. pharmaceutical composition according to claim 1 or 2, which is characterized in that further include the following raw material medicine: haw thorn extract
22-43 parts by weight, extract of mulberry twig 17-42 parts by weight.
8. pharmaceutical composition according to claim 7, which is characterized in that including following bulk pharmaceutical chemicals:
With the poidometer of phloridzin, phloridzin or its pharmaceutically acceptable salt 31-39 parts by weight；
With the poidometer of isoquercitrin, isoquercitrin or its pharmaceutically acceptable salt 18-22 parts by weight；
Haw thorn extract 25-31 parts by weight, extract of mulberry twig 15-19 parts by weight.
9. a kind of pharmaceutical preparation is added conventional auxiliary using the described in any item pharmaceutical compositions of claim 1-8 as active constituent
Material, according to common process, be made clinically acceptable tablet, capsule, powder, pill, granule, syrup, injection,
Solution, mixture, lotion, paint, film, emplastrum, ointment, suppository, paste, gelling agent, aerosol or spray.
10. the described in any item pharmaceutical compositions of claim 1-8 or pharmaceutical preparation as claimed in claim 9 have in preparation
The drug or the application in health care product of weight-reducing or effect for reducing blood fat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711007704.1A CN109700818B (en) | 2017-10-25 | 2017-10-25 | Medicinal composition for losing weight and reducing blood fat and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711007704.1A CN109700818B (en) | 2017-10-25 | 2017-10-25 | Medicinal composition for losing weight and reducing blood fat and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109700818A true CN109700818A (en) | 2019-05-03 |
| CN109700818B CN109700818B (en) | 2021-07-20 |
Family
ID=66253283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711007704.1A Active CN109700818B (en) | 2017-10-25 | 2017-10-25 | Medicinal composition for losing weight and reducing blood fat and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109700818B (en) |
-
2017
- 2017-10-25 CN CN201711007704.1A patent/CN109700818B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109700818B (en) | 2021-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106336445B (en) | The preparation method and application of compound 20 (R) ginseng sapoglycoside Rg 3 | |
| EP2246047A1 (en) | Use of Lanostane derivatives in treating Cachexia | |
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| CN113082166A (en) | Method for preparing health food from herba Dendrobii | |
| CN103479635A (en) | Pharmaceutical composition used for preventing and treating non-alcoholic fatty liver disease and application thereof | |
| CN1557842A (en) | Process for extracting polygonatum polysaccharides, preparing process for medical preparation and use thereof | |
| CN104055947B (en) | A kind of Chinese medicine composition and preparation method containing grape extract | |
| CN107151274A (en) | Algal polysaccharide and its production and use | |
| CN109700819A (en) | A kind of pharmaceutical composition of Weight-reducing and lipid-lowering and preparation method thereof and purposes | |
| CN103906525B (en) | Principal columns of a hall tree extract is preparing the application in treating Gastric Ulcer Treatment | |
| CN109700818A (en) | A kind of pharmaceutical composition of reducing weight and blood fat and preparation method thereof and purposes | |
| CN100361649C (en) | Prepn process of alive adult roach extract | |
| JP2007031302A (en) | Adiponectin production accelerator and metabolic syndrome preventive | |
| WO2013013417A1 (en) | Medicament useful for reducing blood sugar and body weight having the structure of stilbene compounds | |
| CN109700797A (en) | A kind of pharmaceutical composition of weight-reducing and preparation method thereof and purposes | |
| CN109700965A (en) | A kind of composition of Weight-reducing and lipid-lowering and preparation method thereof and purposes | |
| CN101053598B (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
| CN104605344A (en) | Health food for enhancing immunity and preparation method of health food | |
| CN103041390A (en) | Melbine and ezetimibe combined composition medicament for treating nonalcoholic fatty liver disease | |
| CN109646446A (en) | Oleanolic acid type saponin class compound is preparing the application in Weight-lossing hypolipemic medicine | |
| CN103989752A (en) | Pharmaceutical composition used for preventing and treating diabetes mellitus combined with hypertension | |
| CN104138488B (en) | A kind of pharmaceutical composition of reducing blood lipid and its application | |
| CN112641779B (en) | Application of GW441756 in preparation of drugs for preventing and/or treating fatty liver | |
| CN103505481A (en) | Blood lipid reducing composition containing phytosterol and preparation method of composition | |
| CN103505507A (en) | Traditional Chinese medicine composition containing glossy ganoderma and preparation method of composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20190503 Assignee: Jiangsu Jinmao Finance Leasing Co.,Ltd. Assignor: SUZHOU KAIXIANG BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2023320010003 Denomination of invention: A drug composition for reducing weight and blood fat and its preparation method and use Granted publication date: 20210720 License type: Exclusive License Record date: 20230105 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug composition for reducing weight and blood fat and its preparation method and use Effective date of registration: 20230109 Granted publication date: 20210720 Pledgee: Jiangsu Jinmao Finance Leasing Co.,Ltd. Pledgor: SUZHOU KAIXIANG BIOTECHNOLOGY Co.,Ltd. Registration number: Y2023320010020 |
|
| EC01 | Cancellation of recordation of patent licensing contract | ||
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Jiangsu Jinmao Finance Leasing Co.,Ltd. Assignor: SUZHOU KAIXIANG BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2023320010003 Date of cancellation: 20240203 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20210720 Pledgee: Jiangsu Jinmao Finance Leasing Co.,Ltd. Pledgor: SUZHOU KAIXIANG BIOTECHNOLOGY Co.,Ltd. Registration number: Y2023320010020 |